CRISPR

CRISPR1-ttc7a

ID

ZDB-CRISPR-200924-6

Name

CRISPR1-ttc7a

Previous Names

None

Target

ttc7a (1)

Sequence

5' - GAGCTCTGCAGTCACTACGC - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

The PAM site was "AGG" at the 3' end.

Genome Resources

None

Target Location

Constructs

No data available

Genomic Features

Genomic Feature	Affected Genomic Regions
zf3351	ttc7a

Expression

Gene expression in Wild Types + CRISPR1-ttc7a

No data available

Phenotype

Phenotype resulting from CRISPR1-ttc7a

No data available

Phenotype of all Fish created by or utilizing CRISPR1-ttc7a

Phenotype	Fish	Conditions	Figures
intestinal bulb neuromuscular junction ab-sv2 labeling spatial pattern, ameliorated	ttc7a^{zf3351/zf3351}	chemical treatment: leflunomide	Fig. 5 from Jardine et al., 2019
goblet cell vesicle amount, ameliorated	ttc7a^{zf3351/zf3351}	chemical treatment: tiaprofenic acid	Fig. 4 from Jardine et al., 2019
intestinal bulb peristalsis process quality, abnormal	ttc7a^{zf3351/zf3351}	control	Fig. 4 from Jardine et al., 2019
intestinal villus morphology, ameliorated	ttc7a^{zf3351/zf3351}	chemical treatment: tiaprofenic acid	Fig. 4 from Jardine et al., 2019
intestinal bulb epithelium stratified, abnormal	ttc7a^{zf3351/zf3351}	standard conditions	Fig. 4 from Jardine et al., 2019
intestinal bulb peristalsis process quality, ameliorated	ttc7a^{zf3351/zf3351}	chemical treatment: cyanocob(III)alamin	Fig. 4 from Jardine et al., 2019
goblet cell vesicle amount, ameliorated	ttc7a^{zf3351/zf3351}	chemical treatment: cyanocob(III)alamin	Fig. 4 from Jardine et al., 2019
goblet cell vesicle amount, ameliorated	ttc7a^{zf3351/zf3351}	chemical treatment: leflunomide	Fig. 4 from Jardine et al., 2019
intestinal bulb lumen decreased width, abnormal	ttc7a^{zf3351/zf3351}	control	Fig. 4 from Jardine et al., 2019
intestinal bulb peristalsis process quality, ameliorated	ttc7a^{zf3351/zf3351}	chemical treatment: tiaprofenic acid	Fig. 4 from Jardine et al., 2019
intestinal bulb Ab2-akt1 labeling decreased distribution, abnormal	ttc7a^{zf3351/zf3351}	control	Fig. 5 from Jardine et al., 2019
intestinal bulb Ab1-ttc7a labeling absent, abnormal	ttc7a^{zf3351/zf3351}	standard conditions	Fig. S5 from Jardine et al., 2019
intestinal bulb peristalsis process quality, ameliorated	ttc7a^{zf3351/zf3351}	chemical treatment: leflunomide	Fig. 4 from Jardine et al., 2019
goblet cell vesicle increased amount, abnormal	ttc7a^{zf3351/zf3351}	control	Fig. 4 from Jardine et al., 2019
intestinal bulb Ab2-akt1 labeling decreased amount, abnormal	ttc7a^{zf3351/zf3351}	control	Fig. 5 from Jardine et al., 2019
intestinal bulb epithelium apoptotic process process quality, ameliorated	ttc7a^{zf3351/zf3351}	chemical treatment: leflunomide	Fig. 4 from Jardine et al., 2019
intestinal bulb neuromuscular junction ab-sv2 labeling decreased amount, abnormal	ttc7a^{zf3351/zf3351}	control	Fig. 5 , Fig. S5 from Jardine et al., 2019
intestinal bulb lumen width, ameliorated	ttc7a^{zf3351/zf3351}	chemical treatment: cyanocob(III)alamin	Fig. 4 from Jardine et al., 2019
intestinal bulb peristalsis process quality, ameliorated	ttc7a^{zf3351/zf3351}	chemical treatment: fenbufen	Fig. 4 from Jardine et al., 2019
intestinal bulb Ab2-akt1 labeling amount, ameliorated	ttc7a^{zf3351/zf3351}	chemical treatment: leflunomide	Fig. 5 from Jardine et al., 2019
intestinal villus morphology, abnormal	ttc7a^{zf3351/zf3351}	control	Fig. 4 from Jardine et al., 2019
intestinal bulb neuromuscular junction ab-sv2 labeling amount, ameliorated	ttc7a^{zf3351/zf3351}	chemical treatment: leflunomide	Fig. 5 from Jardine et al., 2019
intestinal bulb lumen width, ameliorated	ttc7a^{zf3351/zf3351}	chemical treatment: tiaprofenic acid	Fig. 4 from Jardine et al., 2019
intestinal bulb epithelium apoptotic process increased process quality, abnormal	ttc7a^{zf3351/zf3351}	control	Fig. 4 from Jardine et al., 2019
intestinal bulb lumen width, ameliorated	ttc7a^{zf3351/zf3351}	chemical treatment: leflunomide	Fig. 4 from Jardine et al., 2019
intestinal bulb Ab2-akt1 labeling spatial pattern, ameliorated	ttc7a^{zf3351/zf3351}	chemical treatment: leflunomide	Fig. 5 from Jardine et al., 2019
intestinal bulb neuromuscular junction ab-sv2 labeling decreased distribution, abnormal	ttc7a^{zf3351/zf3351}	control	Fig. 5 , Fig. S5 from Jardine et al., 2019
intestinal villus morphology, ameliorated	ttc7a^{zf3351/zf3351}	chemical treatment: leflunomide	Fig. 4 from Jardine et al., 2019
intestinal villus morphology, ameliorated	ttc7a^{zf3351/zf3351}	chemical treatment: cyanocob(III)alamin	Fig. 4 from Jardine et al., 2019

Citations